Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.76Last Year’s EPS
-1.45Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 13, 2025
|% Change Since: 7.35%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the development pipeline, with major milestones expected in thalassemia and sickle cell disease. Strong revenue growth from PYRUKYND and a robust financial position are positive indicators. However, higher operating expenses and limited revenue growth for PK deficiency were noted as challenges.Company Guidance
During Agios' Fourth Quarter 2024 Conference Call, the company highlighted several key metrics and guidance points for the upcoming year. Agios anticipates a potential approval and commercial launch of their lead product, PYRUKYND, for thalassemia in September 2025, and for sickle cell disease in 2026. The company also reported $10.7 million in net PYRUKYND revenue for the fourth quarter of 2024, reflecting a 51% increase from the previous year. Agios plans to execute a strategy focused on expanding PYRUKYND's indications, advancing its robust pipeline, and strategically deploying capital to sustain and drive growth. Additionally, Agios expects 2025 revenues for PYRUKYND in PK deficiency to remain relatively flat compared to 2024, as they shift focus to the anticipated launch in thalassemia. With a strong balance sheet of approximately $1.5 billion, Agios aims to independently grow and capitalize on upcoming opportunities, underscoring their commitment to deliver innovative therapies for rare diseases.PYRUKYND Revenue Growth
Fourth quarter 2024 net PYRUKYND revenue was $10.7 million, an increase of 51% compared to $7.1 million in the fourth quarter of 2023.
Successful Pediatric Trials
Top line results from the ACTIVATE KIDS Phase III trial showed a 31.6% hemoglobin response in the mitapivat arm compared to 0% in the placebo arm.
Thalassemia and Sickle Cell Disease Pipeline Progress
Potential approval and launch of PYRUKYND in thalassemia expected in September 2025, with sickle cell disease in 2026. Phase III RISE up study for sickle cell disease completed enrollment.
Strong Financial Position
Agios ended the fourth quarter with cash, cash equivalents, and marketable securities of approximately $1.5 billion.
Regulatory and Clinical Milestones
The September 7 PDUFA goal date for PYRUKYND in thalassemia and the Phase III readout of RISE study in sickle cell disease by the end of 2025.
---
AGIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AGIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 13, 2025 | $32.81 | $33.30 | +1.49% |
| Oct 31, 2024 | $46.30 | $44.43 | -4.04% |
| Aug 01, 2024 | $46.40 | $44.50 | -4.09% |
| May 02, 2024 | $33.66 | $34.58 | +2.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Agios Pharma (AGIO) report earnings?
Agios Pharma (AGIO) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Agios Pharma (AGIO) earnings time?
Agios Pharma (AGIO) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AGIO EPS forecast?
AGIO EPS forecast for the fiscal quarter 2025 (Q1) is -1.76.
---